Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5650824 | 1.00 | ATM (0.38) | ATML3MBTL1LMNAHIF1AKDM4E | |
| SCHEMBL28301558 | 0.87 | ADRA2A (0.40) | ATML3MBTL1LMNAHIF1AKDM4E | |
| SCHEMBL15630763 | 0.86 | DPP4 (0.43) | ATML3MBTL1LMNAHIF1AKDM4E | |
| SCHEMBL6896070 | 0.86 | DPP4 (0.43) | ATML3MBTL1LMNAHIF1AKDM4E | |
| SCHEMBL27610060 | 0.86 | CES2 (0.38) | LMNAHIF1AKDM4EDPP4SLC7A5 | |
| SCHEMBL27660598 | 0.85 | ATM (0.38) | ATML3MBTL1LMNAHIF1AKDM4E | |
| SCHEMBL27892297 | 0.82 | AAK1 (0.36) | ATML3MBTL1LTA4HAOC3DPP4 | |
| SCHEMBL27564999 | 0.81 | DPP4 (0.42) | ATML3MBTL1AOC3DPP4KMT2A | |
| SCHEMBL27665873 | 0.81 | DPP4 (0.42) | ATML3MBTL1AOC3DPP4KMT2A | |
| SCHEMBL4937584 | 0.81 | DPP4 (0.42) | ATML3MBTL1AOC3DPP4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7307184-B2 | Processes for preparing oxazolidinone derivatives of β-hydroxyethlamine compounds and for preparing β-hydroxyethlamine compounds | KANEKA CORPORATION (JP) | 2007-12-11 | — | — | US | disclosed |
| US-20040181074-A1 | Process for producing oxazolidinone derivative of beta-hydroxyethylamine compound and for producing beta-hydroxyethlamine compound | KANEKA CORPORATION (JP) | 2004-09-16 | — | — | US | disclosed |
| US-20040049074-A1 | Process for producing 3-amino-2-hydroxypropionic acid derivatives | KANEKA CORPORATION (JP) | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040049074-A1 | Process for producing 3-amino-2-hydroxypropionic acid derivatives | AASDHPPT, HPD, HAAO | ATM 2574/4885L3MBTL1 2670/4885LMNA 1551/4885 |
| US-20040181074-A1 | Process for producing oxazolidinone derivative of beta-hydroxyethylamine compound and for producing beta-hydroxyethlamine compound | HNMT, PNMT, HRH4 | ATM 3529/4885L3MBTL1 3055/4885LMNA 881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.